BURLINGTON, Mass., March 13, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, will be hosting an analyst and investor event on Friday, March 30, 2012, at 7:30 AM ET in New York City. Dr. Bobby W. Sandage, Jr., Coronado's President and CEO, will briefly discuss the Company's clinical development plan of TSO (Trichuris suis ova or CNDO-201) for the treatment of autoimmune diseases and CNDO-109 for the treatment of acute myeloid leukemia. The meeting will include presentations by experts in the fields of immunology and oncology, including:
